Exploration for novel anti-enterovirus compounds and identification of its host targets
Project/Area Number |
25460579
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Virology
|
Research Institution | National Institute of Infectious Diseases |
Principal Investigator |
ARITA MINETARO 国立感染症研究所, その他部局等, 研究員 (70356244)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | エンテロウイルス / 抗ウイルス薬 / 宿主因子 / 複製 / PI4KB / OSBP / VCP/p97 / ウイルス / 膜輸送 / ポリオウイルス |
Outline of Final Research Achievements |
Idendified anti-enterovirus compounds were classified into direct-acting compounds to viral proteins, and PI4KB/OSBP inhibitors. PI4KB/OSBP pathway is required for formation of a virus replication complex by accumulating unesterified cholesterol on virus-induced membrane structure, rather than directly involved in viral RNA synthesis. These results suggested that evaluation of the effectiveness of the PI4KB/OSBP inhibitors is essential in development of anti-enterovirus drug targeting host factor activity.
|
Report
(4 results)
Research Products
(13 results)
-
-
-
-
-
[Journal Article] Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein2015
Author(s)
Strating JR, van der Linden L, Albulescu L, Bigay J, Arita M, Delang L, Leyssen P, van der Schaar HM, Lanke KH, Thibaut HJ, Ulferts R, Drin G, Schlinck N, Wubbolts RW, Sever N, Head SA, Liu JO, Beachy PA, De Matteis MA, Shair MD, Olkkonen VM, Neyts J, van Kuppeveld FJ.
-
Journal Title
Cell reports
Volume: 10
Issue: 4
Pages: 600-615
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-